NAD+ precursor metabolic flux research program
exploratoryresearch program · medium · Mon Apr 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Understand how younger and older healthy adults absorb and metabolize NAD+ precursors and how those precursors raise NAD+ in tissues, including muscle.
Clinical research study administering labeled or unlabeled NMN or NAM orally for 14 days, with blood, urine, stool, and muscle biopsy sample collection.
ClinicalTrials.gov record for tracing metabolic flux of orally administered NAD+ precursors published in 2025.
Oral NAD+ Precursor Metabolic Flux Research Program
exploratoryresearch program · medium · Mon Apr 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Learn how healthy younger and older adults use nicotinamide mononucleotide and nicotinamide to make NAD+, including absorption, metabolism, and tissue NAD+ increases.
Participants take labeled or unlabeled NMN or NAM orally for 14 days, with blood, urine, stool, and muscle biopsy sampling to assess NAD+ production in muscle and other tissues.
ClinicalTrials.gov record published on 2025-04-28.
MIB-725 Healthy Adult Safety and Pharmacology Program
phase 1drug program · high · Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered MIB-725 in community-dwelling healthy adults.
Single-center, open-label, single ascending dose Phase 1a study with up to four cohorts receiving 100, 200, 400, or 800 mg MIB-725.
Phase 1a single ascending dose clinical trial published on ClinicalTrials.gov on 2025-02-11.
MIB-725 NAD+ analog program
phase 1drug program · high · Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate a next-generation MetroBiotech NAD+ analog or precursor candidate for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults.
Single-center, open-label Phase 1a single ascending dose trial of orally administered MIB-725 at 100, 200, 400, and 800 mg dose levels.
Phase 1a single ascending dose study of MIB-725 in healthy adults published on ClinicalTrials.gov.
MIB-626 Exercise and Physical Performance Program
exploratorydrug program · high · Wed Oct 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess effects of MIB-626 with and without a high-intensity multi-dimensional exercise training program in healthy, regularly exercising, highly physically fit adults.
Single-center, randomized, placebo-controlled study of 1000 mg NMN or placebo twice daily for 10 weeks in adults aged 19 to 40.
Clinical trial record published on ClinicalTrials.gov on 2023-10-25.
MIB-626 NAD+ precursor program
phase 2drug program · high · Wed Oct 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop an NAD+ precursor therapy for age-related and disease contexts, including acute kidney injury in COVID-19, Friedreich's Ataxia bioenergetics, and muscle strength/endurance or exercise-related outcomes.
Orally administered nicotinamide mononucleotide/NAD+ precursor evaluated in randomized placebo-controlled clinical studies and disease-focused trials.
Phase 2a trial of MIB-626 versus placebo in adults with COVID-19 infection and stage 1 acute kidney injury; additional clinical studies in Friedreich's Ataxia and healthy exercising adults are listed.
MIB-626 COVID-19 Acute Kidney Injury Program
phase 2drug program · high · Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Determine whether MIB-626 is more efficacious than placebo in adults with COVID-19 infection and stage 1 acute kidney injury for preventing worsening kidney function and attenuating inflammatory response.
Phase 2a placebo-controlled clinical trial evaluating longitudinal changes in serum creatinine concentration and inflammatory response.
Phase 2a clinical trial record published on ClinicalTrials.gov on 2021-10-26.
MIB-626 Friedreich's Ataxia Bioenergetics Program
undiscloseddrug program · high · Mon May 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Test safety and tolerability of short-term NAD+ precursor therapy in adults with Friedreich's Ataxia without overt heart failure and evaluate effects on cardiac and skeletal muscle bioenergetics.
Clinical study of MIB-626 in adults with Friedreich's Ataxia and left ventricular ejection fraction of at least 40%.
Clinical trial record published on ClinicalTrials.gov on 2021-05-17.
MetroBiotech NAD+ biology platform
undisclosedplatform · high
Restore and sustain NAD+ levels to enhance human healthspan and address age-related diseases through proprietary NAD+ precursors and next-generation NAD+ analogs.
Proprietary NAD+ precursor and NAD+ analog drug-development platform focused on cellular energy, mitochondrial function, gene regulation, and cellular resilience.
Company pipeline lists MIB-626 and MIB-725 as active pipeline assets.
MIB-626
phase 1drug program · medium
Restore and sustain NAD+ levels to support mitochondrial function, gene regulation, cellular resilience, healthspan, metabolism, and age-related disease treatment.
Proprietary NAD+ precursor therapeutic evaluated in early human trials as an NAD+ booster.
Early human trials demonstrated increased NAD+ levels within 14 days; a public record also states MetroBiotech kicked off a human trial of a new NAD booster.
Early human trials reportedly demonstrated up to a 200% increase in NAD+ levels within 14 days without drug-related serious adverse events.
MIB-626 Age-Related Disease Program
undiscloseddrug program · medium
Develop MIB-626 for aging-related conditions including Alzheimer's disease, chronic kidney disease, muscle strength and endurance, and acute kidney injury.
Clinical-stage development of proprietary NAD+ precursor MIB-626.
Company site identifies MIB-626 as a pipeline program for age-related conditions.
MIB-725
undiscloseddrug program · medium
Develop next-generation NAD+ analog therapeutics for aging, metabolism, and age-related diseases.
Proprietary NAD+ analog / NAD+ restoration therapeutic program.
Listed in MetroBiotech pipeline as a program alongside MIB-626.
NAD+ restoration platform
undisclosedplatform · high
Restore and sustain NAD+ levels as a therapeutic strategy for mitochondrial function, gene regulation, cellular resilience, healthspan, metabolism, and age-related diseases.
Platform based on proprietary NAD+ precursors and next-generation NAD+ analogs.
MetroBiotech describes its platform as the basis for MIB-626 and next-generation NAD+ analog development, with early human trial evidence of NAD+ increases.
Site material states early human trials showed up to a 200% increase in NAD+ levels within 14 days without drug-related serious adverse events.
Proprietary NAD+ Precursor Platform
undisclosedplatform · high
Restore and sustain NAD+ levels to enhance healthspan and address age-related diseases through effects on mitochondrial function, gene regulation, and cellular resilience.
Development of proprietary NAD+ precursors and next-generation NAD+ analogs, including MIB-626 and MIB-725.
Company pipeline lists MIB-626 and MIB-725 as active programs.
